Drug intelligence / Profile preview

mRNA-4851

Development stage: Preclinical
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

mRNA-4851 is an mRNA therapeutic developed through an exclusive collaboration between Moderna and AstraZeneca. It leverages Moderna's mRNA technology platform to target various diseases. The initial focus of the collaboration included cardiovascular, metabolic, and renal diseases, as well as selected oncology targets. The partnership later expanded to encompass preclinical immuno-oncology programs. Moderna is responsible for discovery and early development, with AstraZeneca leading later stages of development.

Beyond the preview

Go deeper on mRNA-4851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-4851.

Explore the full profile